Revolution Medicines, Inc.

Revolution Medicines on April 13 presented breakthrough results from a study of a drug against the deadliest type of cancer. Freedom Holding co-founder Igor Klyushnev believes that this story deserves to be directed by a talented director. It is about how breakthrough clinical data is combined with high dynamics of events. And most importantly, it is a story about people who turned out to be ready for important events.

How oncology company Revolution Medicines monetized a year of operations in 48 hours 

Alamar Biosciences, Inc.

Preliminary trading in shares of biotech company Alamar Biosciences, a protein sequencing company that enables disease research and diagnosis, has begun on the Freedom client trading system. Alamar is one of several biotech companies that have continued to go public this year despite volatile market conditions, Reuters <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/kailera-alamar-launch-us-ipos-biotech-listings-gather-momentum-2026-04-13/">notes</a>. Later on April 17, Alamar Biosciences securities will appear on the Nasdaq exchange under the ticker ALMR. To participate, click on the ticker <a href="https://tap.freedom24.com/to/quote/HMH.US?utm_source=stocks&amp;utm_medium=HMH.US&amp;utm_campaign=pfu17521958">ALMR</a>.

Alamar IPO: shares of the biotech, whose mission is the early diagnosis of diseases, became available

Planet Fitness, Inc.

Novo Nordisk A/S

Eli Lilly and Company

The hype around GLP-1-class weight loss drugs is opening up new growth opportunities for fitness club chain Planet Fitness, investment bank Stifel predicts. "We believe GLP-1 users could significantly increase fitness club subscriptions in the coming years," analyst Chris O'Call wrote in a note to clients <a href="https://www.cnbc.com/2026/01/16/this-gym-stock-could-see-a-boost-from-increase-weight-loss-pill-use-says-stifel.html">quoted</a> by CNBC. He reiterated a buy recommendation on Planet Fitness shares and a $130 target, up 31% from the Jan. 15 close.

Stifel expects fitness chain's stock to rise 30%. How will a diet pill help them? 

Sanofi

The corporation is diversifying its sources of growth beyond its key asthma drug Dupixent

Sanofi is expanding its vaccine business. It will buy Dynavax for $2.2 billion

They are different from the already-hit Wegovy and Zepbound

Lilly and Novo simultaneously filed applications for approval of new obesity drugs

Medline Inc.

Analysts saw this placement as a signal for the market

Medline shares soared 41% after this year's biggest IPO. Should you buy them?

The company has raised over $6 billion through its listing and has a valuation of over $50 billion

Biggest IPO of the year: shares of medical products giant Medline become available

Company's experimental multiple sclerosis drug fails to meet key goal in clinical trial

Sanofi's stock is down. Its sclerosis drug suffers 'double blow'

Lumexa

The company goes public on the Nasdaq under the ticker LMRI

Lumexa IPO: trading in securities of the network of diagnostic imaging centers has started 

Moderna, Inc.

Novavax, Inc.

Pfizer Inc.

The U.S. Food and Drug Administration has threatened to tighten its vaccine approval process

Moderna and Novavax shares fall amid reports of 10 likely deaths after vaccination

Merck & Co., Inc.

Regeneron Pharmaceuticals, Inc.

Increased volatility and doubts about AI's prospects have pushed the market toward defensive stocks

Healthcare has become a safe haven for investors: the sector grew by 10% in November


The White House also secured reductions in the cost of Wegovy and Pfizer's cancer drug